Hirsutism surgery

Hirsutism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hirsutism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

MRI

Echocardiography or Ultrasonography

Treatment

Medical Therapy

Pharmacological therapy

Non-pharmacological therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hirsutism surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hirsutism surgery

CDC on Hirsutism surgery

Hirsutism surgery in the news

Blogs on Hirsutism surgery

Directions to Hospitals Treating Hirsutism surgery

Risk calculators and risk factors for Hirsutism surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2], Rasam Hajiannasab M.D.[3], Eiman Ghaffarpasand, M.D. [4]

## Overview

[edit | edit source]

The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either ovarian tumor, adrenal tumor, perimenopausal or postmenopausal women with severe hyperandrogenism who are candidated for oophorectomy, or bariatric surgery for severe obesity.

## Surgery

[edit | edit source]

PF2LH6CuesY|500}}

* The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either:
* Ovarian tumor[1]
* Adrenal tumor[1]
* Perimenopausal or postmenopausal women with severe hyperandrogenism are candidated for oophorectomy[2][3]
* Bariatric surgery is an additional option for PCOS women with severe obesity or obesity with metabolic comorbidities[4][5]

## References

[edit | edit source]

1. ↑ 1.0 1.1 Franks, Stephen (2012). "The investigation and management of hirsutism". Journal of Family Planning and Reproductive Health Care. 38 (3): 182–186. doi:10.1136/jfprhc-2011-100175. ISSN 1471-1893.
2. ↑ Souto SB, Baptista PV, Braga DC, Carvalho D (2014). "Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism". Arq Bras Endocrinol Metabol. 58 (1): 68–75. PMID 24728167.CS1 maint: Multiple names: authors list (link)
3. ↑ Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B; et al. (2010). "Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature". Exp Clin Endocrinol Diabetes. 118 (5): 291–7. doi:10.1055/s-0029-1225351. PMID 20198556.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
4. ↑ Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012). "Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group". Fertil. Steril. 97 (1): 28–38.e25. doi:10.1016/j.fertnstert.2011.09.024. PMID 22153789.
5. ↑ Spritzer PM (2014). "Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances". Arq Bras Endocrinol Metabol. 58 (2): 182–7. PMID 24830595.